

# **BIOSIMILARS**

---

**A Guide to Regulatory and Intellectual Property Issues  
January 2016**



**GOODWIN**

# BIOSIMILARS

## A Guide to Regulatory and Intellectual Property Issues

**Elaine Herrmann Blais**

617.570.1205

eblais@goodwinprocter.com

**Robert V. Cerwinski**

212.459.7240

rcerwinski@goodwinprocter.com

**Kristin R. Davenport**

202.346.4153

kdavenport@goodwinprocter.com

**Sarah Fink**

212.459.7202

sfink@goodwinprocter.com

**Jennifer L. Ford**

617.570.1087

jford@goodwinprocter.com

**Cynthia L. Hardman**

212.459.7295

chardman@goodwinprocter.com

**Mark A. Heller**

202.346.4107

mheller@goodwinprocter.com

**William G. James**

202.346.4046

wjames@goodwinprocter.com

**Parker D. Kasmer**

202.346.4127

pkasmer@goodwinprocter.com

**Alexandra Lu**

617.570.8275

alu@goodwinprocter.com

**Nicholas K. Mitrokostas**

617.570.1913

nmitrokostas@goodwinprocter.com

**Krupa K. Parikh**

202.346.4059

kparikh@goodwinprocter.com

**Stephanie Philbin**

202.346.4148

sphilbin@goodwinprocter.com

**Joshua Weinger**

617.570.8361

jweinger@goodwinprocter.com

**Joshua A. Whitehill**

212.459.7289

jwhitehill@goodwinprocter.com

**Eleanor M. Yost**

202.346.4502

eyost@goodwinprocter.com

# TABLE OF CONTENTS

Introduction .....	1
Market Developments for Biosimilars.....	3
The Current Market for Biologics .....	3
The Market Potential for Biosimilars: Insights from Europe and Asia.....	9
Biosimilar Uptake in Europe .....	12
Biosimilar Uptake in Asia .....	14
Approval Pathways and Timelines for Follow-On Biologics in the U.S. ....	15
Biosimilar Application Under 262(k).....	15
Definition of Key Terms .....	15
Contents of Application .....	16
Timing of Approval .....	16
Biologics License Application Under Section 262(a) .....	17
Abbreviated New Drug Application .....	19
Comparison of Approval Pathways and Timelines.....	20
Mechanics of the Patent Dance Under the BPCIA .....	22
Use of Post-Grant Patent Proceedings as a Tool in the Decision Making Process.....	25
Recent Legal Developments Concerning the BPCIA .....	28
Overview: “Mystery Inside an Enigma”.....	28
<i>Amgen v. Sandoz</i> .....	30
<i>Janssen v. Celltrion</i> .....	35
<i>Amgen v. Apotex</i> .....	36
<i>Amgen v. Hospira</i> .....	38
Biosimilars at FDA.....	40
Biosimilar Application Activity at FDA .....	40
FDA Guidances for Biosimilar Applications .....	41
Naming.....	47
Labeling.....	48
Citizen Petition Activity .....	50
FDA is Easing Burden for Sponsors with Biosimilar Approvals from the EMA .....	51
FDA Likely to Require Substantial Clinical Data for “Interchangeable” Biosimilars .....	52
Regulation of Biosimilars Outside of the U.S. ....	54
Exclusivity Under the Trans-Pacific Partnership Agreement (TPP).....	54
Europe .....	55
India .....	58
Japan .....	59
Korea.....	60
China.....	61
Other Recent Legal Developments That May Impact Biosimilars .....	62
Recent Case Law on Induced Infringement and Pharmaceutical Patents.....	62
Recent Case Law Affecting the Statutory Safe Harbor.....	63
Appendix Materials .....	Tabs 1-3



# APPENDIX MATERIALS

	TAB
U.S. ....	1
42 U.S.C. § 262	
United States Patent and Trademark Office, 2014 Interim Guidelines on Patent Subject Matter Eligibility, 79 Fed. Reg. 74618, December 2014	
Trans-Pacific Partnership: Chapter 18, Intellectual Property	
FDA Guidance (final): Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, April 2015	
FDA Guidance (final): Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, April 2015	
FDA Guidance (final): Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product, April 2015	
FDA Guidance (final): Formal Meetings between FDA and Biosimilar Biotechnical Product Sponsors or Applicants, November 2015	
FDA Guidance (draft): Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, May 2014	
FDA Guidance for Industry (draft): Reference Product Exclusivity for Biologic Products Filed Under 351a of PHS Act, August 2014	
FDA Guidance (draft): Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, May 2015	
FDA Guidance: Citizen Petitions and Petitions for Stay of Action Subject to Subject 505(q), November 2014	
FDA Guidance: Nonproprietary Naming of Biological Products, August 2015	
Court Decision: <i>AbbVie Deutschland Gmbh &amp; Co. v. Janssen Biotech, Inc.</i>	
Court Decision: <i>Alice Corp. v. CLS Bank Int'l</i>	
Court Decision: <i>Amgen Inc. v. Sandoz Inc.</i>	
Court Decision: <i>Ariosa Diagnostics, Inc. (f/k/a Aria Diagnostics) v. Sequenom, Inc.</i>	
Court Decision: <i>Association for Molecular Pathology v. Myriad Genetics, Inc.</i>	
Court Decision: <i>In re Roslin Institute</i>	
Court Decision: <i>Mayo Collaborative Services v. Prometheus Laboratories, Inc.</i>	
Court Decision: <i>Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc.</i>	
EMA .....	2
European Medicines Agency: Guideline on Similar Biological Medicinal Products, October 2014	
European Medicines Agency: Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (Revision 1), May 2014	
European Medicines Agency: Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues, February 2006	
Asia .....	3
India	
Government of India, Department of Biotechnology: Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India, 2012	
Japan	
Guideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics, March 2009	
Korea	
Korea Food & Drug Administration: Evaluation Guidelines for Biosimilars, July 2009	